StockData
Molecular Partners AG logo

Molecular Partners AG (MOLN) stock

MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30
$2.67−0.19 (-6.82%)

Close on Nov 18, 2026Market cap $107.60MP/E –Yield –

Molecular Partners operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2025 it was -CHF 58.12M. The highest annual figure on record is CHF 116.61M in fiscal 2022.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-CHF 58.12M–
FY2024Dec 31, 2024-CHF 61.22M–
FY2023Dec 31, 2023-CHF 61.11M-152.4%
FY2022Dec 31, 2022CHF 116.61M–
FY2021Dec 31, 2021-CHF 63.42M–
FY2020Dec 31, 2020-CHF 58.33M–
FY2019Dec 31, 2019-CHF 36.66M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-CHF 13.59M–
Q2 FY2025Jun 30, 2025-CHF 17.32M–
Q2 FY2024Jun 30, 2024-CHF 15.98M–
Q2 FY2023Jun 30, 2023-CHF 15.88M–
Q2 FY2022Jun 30, 2022-CHF 6.29M–

More Molecular Partners figures

See a number that looks wrong?